STOCK TITAN

Armistice Capital (VSTM) reports 3.54M shares, 5.30% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Verastem, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,536,000 shares of common stock, representing 5.30% of the class as of 12/31/2025. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under its Investment Management Agreement; the Master Fund is the direct holder. The filing is a joint Schedule 13G signed on 02/17/2026.

Positive

  • None.

Negative

  • None.

Insights

Armistice holds a 5.30% stake (3,536,000 shares) reported as of 12/31/2025.

Armistice Capital is disclosed as the investment manager exercising shared voting and dispositive power over 3,536,000 shares, which the filing labels as 5.30% of common stock. The Master Fund is identified as the direct holder.

Timing: the position is reported as of 12/31/2025 with the joint filing signed 02/17/2026. Subsequent filing updates would show changes in this position.

Filing is a joint Schedule 13G disclosure with standard attribution and disclaimers.

The statement explains that Armistice Capital, as investment manager, may be deemed to beneficially own the securities held by Armistice Capital Master Fund Ltd., while the Master Fund disclaims beneficial ownership due to its inability to vote or dispose under the Investment Management Agreement.

Signatures and a joint filing agreement are included and dated 02/17/2026; this aligns with routine Schedule 13G reporting obligations for institutional investors.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in Verastem (VSTM)?

Armistice Capital reports beneficial ownership of 3,536,000 shares, equal to 5.30% of Verastem's common stock as of 12/31/2025. The Master Fund is the direct holder and Armistice is the investment manager.

Who is listed as the reporting persons on the Schedule 13G for VSTM?

The filing lists Armistice Capital, LLC and Steven Boyd as the reporting persons, with Armistice as the investment manager and Mr. Boyd as its managing member. The joint statement is signed 02/17/2026.

Does the Schedule 13G state who holds voting power over the reported shares?

Yes. The filing states shared voting power of 3,536,000 shares and shared dispositive power of 3,536,000, with no sole voting or dispositive power reported by the reporting persons.

Who is the direct holder of the shares Armistice reports for VSTM?

The direct holder is identified as Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, and it has the right to receive dividends or proceeds from sale of the reported securities.

When was the Schedule 13G signed and filed?

The joint Schedule 13G bears signatures by Steven Boyd dated 02/17/2026. The position is reported with an ownership date of 12/31/2025 in the filing.
Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

430.08M
70.63M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM